Data supporting the findings are available in the results section, and all the 61 sequences generated for this study were submitted to Genbank under the following accession numbers MK995400 - MK995457 and MK995397 - MK995399.

Introduction {#sec006}
============

The introduction of highly active antiretroviral therapy (HAART) has significantly decreased the rate of Human Immunodeficiency virus (HIV)--related morbidity and mortality \[[@pone.0235958.ref001]\]. However, with the new goal currently endorsed by the joint United Nations program on AIDS (UNAIDS) aimed at ending AIDS by 2030, through the 90-90-90 treatment target by 2020 \[[@pone.0235958.ref002],[@pone.0235958.ref003]\], and coupled with the WHO recommendation to test and treat \[[@pone.0235958.ref004]\], there have been an increase in the on-going scale-up of antiretroviral treatment (ART) most especially in sub-Saharan Africa (SSA) \[[@pone.0235958.ref005]\]. However the increased scale-up has led to undesired consequences like the selection and emergence of HIV drug resistance (HIVDR) variants, which remains a major obstacle, limiting the efficacy of commonly available antiretroviral (ARVs) \[[@pone.0235958.ref006]--[@pone.0235958.ref008]\]. HIVDR remains a huge problem as it currently involves not only patients on antiretroviral-treatment, but equally drug-naïve individuals carrying HIV-resistant strains \[[@pone.0235958.ref009]\]. Based on the World Health Organisation (WHO) classification of HIVDR, it is classified into three main categories; pre-treatment drug resistance \[PDR, (among ART initiators or re-initiators)\], transmitted drug resistance (TDR, among recently-infected individuals), and acquired drug resistance \[ADR, (at ART failure)\] \[[@pone.0235958.ref010]\]. ADR occurs when HIV mutations emerge as a result of viral replication in individuals receiving ARV drugs. Transmitted HIV drug resistance (TDR) are resistances detected in ARV drug-naive patients with no history of ARV drug exposure. While pre-treatment HIV drug resistance (PDR) is resistance detected in ARV drug-naive people initiating ART or people with prior ARV drug exposure initiating or reinitiating first-line ART. PDR can either be transmitted or acquired drug resistance. It may have been transmitted at the time of infection (TDR), or it may be acquired by virtue of prior ARV drug exposure \[[@pone.0235958.ref010]\]. The transmission of HIV-1 drug resistance from treatment-experienced patients to newly infected individuals has been observed in developed countries with access to antiretroviral therapy \[[@pone.0235958.ref010]--[@pone.0235958.ref013]\]. In 2015, a meta-analysis conducted in sub-Saharan Africa (SSA), South/Southeast Asia(SSEA), Upper-income Asian countries, Latin America/Caribbean, Europe and North-America showed the median overall prevalence of transmitted HIV drug resistance was 2,8%, 2,9%, 5.6%, 7.6%, 9.4% and 11.5% respectively \[[@pone.0235958.ref014]\].

Cameroon a sub-Saharan African country situated in Central West Africa, harbours 67% of the Worlds HIV infection \[[@pone.0235958.ref015]\]. Cameroon endorsed the WHO test and treat recommendation in June 2016 \[[@pone.0235958.ref016]\]. Before the endorsement, in 2011 the prevalence of HIV/AIDS epidemic for women was almost twice that of men (5.6% Vs 2.9%) with the greatest epidemiological burden in urban settings \[[@pone.0235958.ref017]\]. Meanwhile ARV drugs through the Ministry of Public Health have been made available free since May 2007 in the National territory of Cameroon for the management of people living with HIV/AIDS (PLHIV) \[[@pone.0235958.ref018],[@pone.0235958.ref019]\], with a total of 151 HIV treatment centers all around the national territory by the end of 2011 \[[@pone.0235958.ref019],[@pone.0235958.ref020]\]. By 2016, there were 205,359 clients receiving HAART \[[@pone.0235958.ref016]\], as compared to 145,038 clients in 2014 \[[@pone.0235958.ref021]\], showing a rapid scale-up of HAART.

Studies carried out in some parts of Cameroon showed a high genetic diversity of HIV with the CRF02_AG being the most predominant form \[[@pone.0235958.ref022]\]. Several TDR studies conducted in some rural and urban settings of the country found rates varying from low (4.9%) to moderate (9.8%), then to high (24%) levels of drug resistance \[[@pone.0235958.ref021],[@pone.0235958.ref023]--[@pone.0235958.ref026]\] with a greater epidemiological burden in the urban than rural setting. In spite of the availability of findings with a global estimate at national level, there is limited evidence on the level of PDR at regional level, and this pitfall could have different implications according to geographical localities. More so, these studies do not focused on assessing HIV-1 genetic diversity and its possible effects on PDR. The Northwest region having the second highest HIV epidemiological burden \[[@pone.0235958.ref017]\] would require evidence on PDR in both rural and urban settings. Our objectives were; to ascertain PDR in both rural and urban settings in this region, to determine class specific resistance to NRTI, NNRTIs and PIs and its potential association with subtype distribution and CD4 staging for better ART program implementation.

Materials and methods {#sec007}
=====================

Study design and settings {#sec008}
-------------------------

A descriptive cross-sectional study design was conducted among HIV-infected ART-naïve adults of both sexes enrolled from two clinical study sites; the Bamenda Regional Hospital (an urban setting) and the Mbingo Baptist Hopital-Kom (a rural setting) during a period of 4 months, ranging from February through April 2017.

Study participants {#sec009}
------------------

Eligible participants were those diagnosed HIV-positive, prior to ART initiation, aged 18 years and above, and registered in our study sites.

The sample size of study participants was estimated assuming a 6% error margin and a 95% CI with a PDR rate of 7.55% as earlier described \[[@pone.0235958.ref005]\], using the following formula: $$\begin{array}{l}
{\quad N = \frac{Z^{2}\ x\ \left( p \right)\left( 1 - p \right)}{d²}} \\
{Where:\left\{ \begin{array}{l}
{\mathbf{N}‐\mathit{the}\ \mathit{minimum}\ \mathit{sample}\ \mathit{size}} \\
{\mathbf{Z}‐1.96\ \mathit{for}\ a\ 95\%\ \mathit{Confidence}\ \mathit{interval}} \\
{p - \mathit{prevalence}\ \mathit{of}\ \mathit{patients}\ \mathit{presenting}\ \mathit{with}\ \mathit{resistant}\ \mathit{strain};\ p = 0.075\ \lbrack\mathit{ref}\ 5\rbrack} \\
{\mathbf{d} - \mathit{error}\ \mathit{margin}\ \mathit{set}\ \mathit{at}\ 6\%} \\
\end{array} \right.} \\
\end{array}$$

A total sample size of 68 was obtained after calculation. Seventy (70) treatment naïve patients were recruited, of these 63 samples amplified after RT-PCR and 61 sequences were retained for analysis after sequencing reaction. These patients were evenly distributed among the two selected ART facilities (One urban and one rural) The clinical study sites were selected following a community mapping done during former HIV/AIDs intervention programs in the North West region of Cameroon. With the approval of the HIV/AIDs center coordinators in each selected facility, case folders were selected and with the help of the psychosocial workers and community relay agents, the study participants were identified. Advocacy counselling to the selected participants were made and the participants were then included in the study.

Sample collection {#sec010}
-----------------

Following the sampling frame, two health facilities (one rural and one urban) were selected by simple random sampling method using balloting procedure. Hospital case files were selected by simple random sampling method using balloting procedures. The units of selection were positively diagnosed HIV naïve participants. The participants from each selected case file was then interviewed and if the respondent was below 18 years or refused to participate the next case file was then chosen. A pre-tested, structured, interviewer-administered questionnaire with open and closed ended questions was used for collecting the respondent's responses. The questionnaire consisted of the socio-demographic and clinical characteristics of the respondents. The socio-demographic parameters consisted of the participants age and sex while the clinical characteristics captured 3 sub-sections; The WHO clinical staging, the immunological status of the participants at time of sample collection (CD4 count) and the third subsection classified the mutations based on the Stanford database list for relevant mutations against NRTIs, NNRTIs and PI. on the antiretroviral drug class identified. A pre-testing of the questionnaire was done in two other selected health facilities each from a rural and urban setting Eight millilitres of whole blood was collected by a trained staff into EDTA blood collection tubes and four (04) plasma aliquots each of 1ml were constituted from every blood sample by centrifugation at 1800 rpm for 10mins and stored at -80°C. At the end of the collection process, the samples were transported with the help ice packs coolants within a period of 5 hours to the "Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management" (CIRCB) where they were stored at -80^0^ C for molecular analysis and bioinformatics.

Sequencing procedure {#sec011}
--------------------

Viral RNA was extracted from 1ml aliquot of plasma using the *Purelink™ Viral RNA/DNA kit* following the protocol specifications. A total of 10μl RNA was extracted and was used as a template to amplify the reverse transcriptase and protease genes of HIV-1.

RNA extracts from the patients were amplified using a previously validated in-house reverse transcriptase polymerase chain reaction \[[@pone.0235958.ref027]\].

Amplified samples from the *pol* region were completely sequenced in the sense and antisense orientations using an automated sequencer (ABI 3130 Genetic Analyzer) with the help of seven different overlapping sequence-specific primers: `5’ AGC AGA CCA GAG CCA ACA GC 3’`(2140--2159 gag), `5’ CCA TCC ATT CCT GGC TTT AAT 3’` (2582--2602 pol`), 5’ CAG GAA TGG ATG GCC CAA AA 3’` (2590--2609 pol), `5’ TTG TAC AGA AAT GGA AAA GGA AGG 3’` (2660--2683 pol), `5’ CCC TGT GGA AAG CAC ATT GTA 3’` (2985--3004, with an insertion), `5’ GCT TCC ACA GGG ATG GAA A 3’` (2993--3011 pol), `5’ CTA TTA AGT CTT TTG ATG GGT CA 3’` (3506--3528 pol) \[reference from the HXB2 strain from the Los Alamos National Laboratory database using the Sequence Locator and QuickAlign tools: <http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html>\]. The sequencing primers were designed based on the analysis of highly conserved regions among HIV-1 subtypes. The reaction mixture for the sequencing reaction contained 8 μl ABI PRISM Big Dye Terminator (Perkin-Elmer), 4.8 μl water, 3.2 μl primer (1 pmol) and 4 μl of purified cDNA (40 ng), for a total volume of 20 μl. The sequencing conditions were as follows: 35 cycles (96°C, 10 s; 55°C, 10 s; 60°C, 4 min); 1 cycle of 4°C for 30 min. The quality of each sequence was ensured by covering the PR-RT region with at least two sequence segments (one forward and one reverse). The sequencing product was purified using Sephadex G-50 resin (Sigma-Aldrich) in order to eliminate excess primers, unincorporated dideoxynucleotides (ddNTPs), and salts.

Sequences obtained were aligned in BioEdit Sequence Alignment Editor Version 7.2.6 using CLUSTAL W \[[@pone.0235958.ref028]\] and compared with reference sequences of all known HIV-1 group M subtypes (A1, A2, B, C, D, F1, F2, G, H, J, and K). Circulating recombinant forms (CRFs) were downloaded from the Los Alamos HIV sequence database ([www.hiv-web.lanl.gov](http://www.hiv-web.lanl.gov)). The Phylogenetic tree was constructed using the MEGA version 7 software package with a bootstrap robustness of 1,000 replicates ([http://megasoftware.net](http://megasoftware.net/)). Sequences with \<70% homology were confirmed using the softwares RDP (Recombinant Detection Programme) and SplitsTree 4 version 4.14.4.

The amplified reverse transcriptase DNA sequences were analysed for potential drug resistance mutations using Stanford HIVdb algorithms (<http://hivdb.standford.edu/>) version 8.5, considering possible revertant mutants as sentinel of minority variants. Based on a genotypic susceptibility score, drug resistant mutations detected were classified as high, intermediate or low-level resistance to NRTIs, NNRTIs or PIs.

All the 61 sequences generated for this study were submitted to Genbank using the accession numbers MK995400---MK995457 and MK995397---MK995399. For bivariate analysis, Fischer's exact test was used to compare differences between proportions. Significance level was set at p\<0.05

Ethical considerations {#sec012}
----------------------

Administrative approval for the study was issued by the Regional Delegation of Public Health of the Northwest region and from the Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (Ref. N° 2112/016L/CIRCB/DIR/CL); ethical approval for the research was obtained from the Cameroon National Ethics Committee for Research on Human Health (Ref. N° 2017/03/893/L/CNERSH/SP), the Institutional Review Board (IRB) of Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I (Ref. N° 211/UYI/FMSB/VDRC/CSD) and of the IRB of the CBC Health facility (IRB2017-02). Following study information to each respondent, a written informed consent was obtained after having been clearly intimated with the objectives, methodology, advantages and potential risks involved in the study. Participation was voluntary throughout the study and any participant was free to decline participating in the study at any time without any prejudice. Participants were treated equally irrespective of their social status and other related status. Confidentiality and privacy were ensured by using no identification information. Genotypic results were freely returned to participants for possible clinical benefits in their therapeutic management.

Results {#sec013}
=======

Characteristics of the study population {#sec014}
---------------------------------------

The socio-demographic and clinical characteristics of the successively sequenced treatment naïve patients' samples from rural (n = 30) and urban (n = 31) settings in Northwest Cameroon are recorded in [Table 1](#pone.0235958.t001){ref-type="table"}.

10.1371/journal.pone.0235958.t001

###### Demographic and clinical characteristics of treatment naïve patients (n = 61) recruited between February-April 2017.

![](pone.0235958.t001){#pone.0235958.t001g}

  Characteristics                          Patients (n = 61)
  ---------------------------------------- -------------------
  Sex:                                     
      Women, n (%)                         35 (57.4)
  Men, n (%)                               26 (42.6)
  Median age, years (IQR)                  37 (29.5--43)
  Median CD4 cell count, cells/μl (IQR):   
      Rural setting                        161 (96--322)
      Urban setting                        184 (35--387)

IQR: Interquartile range.

The participants median age was 37 years \[IQR: 29.5--43\] and 57.4% (35/61) of the study participants were female; Female to male ratio of 1.3:1. At the point of study, the overall study participants in both settings showed an advanced stage of disease: Median CD4, Rural; 161 cells/mm^3^ \[IQR: 96--322\], Urban; 184 cells/mm^3^ \[IQR: 35--387\].

Prevalence of HIV-1 drug resistance {#sec015}
-----------------------------------

In the rural setting 30/31 protease-reverse transcriptase samples were successively genotyped as opposed to 31/32 in the urban setting. This gave a sequencing performance of 96.8% in both settings. The pre-treatment drug resistance (PDR) prevalence was found to be 9.8% (6/61) harbouring at least one drug resistance-associated mutation, with a slightly greater percentage of resistance mutations to Non-nucleotide Reverse transcriptase Inhibitors \[NNRTIs\] (8.2%) against Nucleotide Reverse transcriptase Inhibitors \[NRTIs\] (4.9%). Four patients in the urban setting (12.9%) had at least one drug resistance while 2 patients in the rural setting (6.7%) had at least one drug resistance. The patients with PDR was almost doubled in the urban setting \[12.9% (4/31)\] as compared to the rural setting \[6.7% (2/30)\]; *p* = 0.352. In four (4) of the patients carrying resistance associated mutations in the urban setting, 6 resistance mutations to NRTIs: \[M41L (2), E44D (1), K65R (1), K70E (1), M184V/I (2), K219R (1)\] and 6 resistance mutations to NNRTIs: K103N (1), E138A/G (2), V179E (1), M230L (1), K238T (1), P225H (1)\] were found. In the two patients carrying resistance mutations in the samples from the rural setting, resistance mutations to only NNRTIs E138A (1) and Y188H (1)\] were found. No mutations conferring resistance to Protease Inhibitors \[PIs\] were found in our study.

Subtypes of HIV-1 protease -reverse transcriptase sequences {#sec016}
-----------------------------------------------------------

The samples were obtained from patients who were infected with HIV-1 virus. Overall, CRF02_AG was the most predominant clade \[72.2% (44/61)\] with similar rates found between urban \[74.2% (23/31)\] vs rural \[70.0% (21/30)\] setting, *p-value* = 0.715.

Despite similar rates of CRF02_AG found in both settings, the rural setting showed two more genetic variant \[8 subtypes; A~1~ (3), G (1), F~2~ (1), CRF02_AG (21), CRF06_cpx (1), CRF11_cpx (1), and CRF18_cpx (1) and an unclassified recombinant of A~1~/F~2~ (1)\], compared to the Urban setting \[5 subtypes A~1~ (3), G (3), F~2~ (1), CRF02_AG (23) and CRF18_cpx (1)\]. The prevalence [Fig 1](#pone.0235958.g001){ref-type="fig"} shows the phylogenetic tree of the entire study sequence analysed. However the study found no association between subtype distribution (CRF02_AG vs Non-CRF02_AG) and the occurrence of PDR mutation \[CRF02_AG \[9.1% (4/44)\], Non-CRF02_AG \[11.8% (2/17)\]; *p* = 1.000\], as shown in [Table 2](#pone.0235958.t002){ref-type="table"}. Moreover patients with CD4\<200 cells/mm^3^ were found to have a higher PDR prevalence rate \[14.7% (5/34)\] as compared to those with CD4 ≥ 200 cells/mm^3^, however there was no significant association between CD4 staging and the occurrence of drug resistant mutation \[3.7% (1/27)\]; *p* = 0.214\] ([Table 2](#pone.0235958.t002){ref-type="table"})

![Phylogenetic tree of HIV-1 isolates from patients in the Northwest region of Cameroon, aligned using Clustal W, analysis was performed using the neighbour-joining method and MEGA 5.0.](pone.0235958.g001){#pone.0235958.g001}

10.1371/journal.pone.0235958.t002

###### Distribution of drug resistance by HIV-1 clade and WHO CD4 classification.

![](pone.0235958.t002){#pone.0235958.t002g}

  Clade                    Presence of DR (n)       Absence of DR (n)       Total (DRM %)
  ------------------------ ------------------------ ----------------------- -------------------
  CRF02_AG                 4                        42                      44 (9.1)
  Non-CRF02_AG             2                        15                      17 (11.8)
                           P-value = 1.000                                  
  **CD4 Count**            **Presence of DR (n)**   **Absence of DR (n)**   **Total (DRM %)**
  CD4 \< 200 cells/mm^3^   5                        29                      34 (14.7)
  CD4 ≥ 200 cells/mm^3^    1                        26                      27 (3.7)
                           p = 0.214                                        

DRM: Drug resistance mutation; DR: Drug resistance.

Detailed characteristics of patients harbouring pre-treatment drug resistance has been provided in [Table 3](#pone.0235958.t003){ref-type="table"}, considering their geographical locations, their CD4-count level, their HIV-1 subtype, and the patterns of resistance mutations detected.

10.1371/journal.pone.0235958.t003

###### Drug resistance mutation patterns.

![](pone.0235958.t003){#pone.0235958.t003g}

  Patient ID         CD4 count (cells/mm3)   Drug resistance mutations   Subtype                      ART facility setting              
  ------------------ ----------------------- --------------------------- ---------------------------- ---------------------- ---------- -------
  ORM06_CIRCB_2017   43                      M41L, E44EAD                \-                           \-                     CRF02_AG   Urban
  OSN03_CIRCB_2017   310                     K65R, M184I                 V179E, M230L                 \-                     CRF02_AG   Urban
  OAM21_CIRCB_2017   1                       M41L, K70E, M184V, K219R    K103N, E138G, P225H, K238T   \-                     CRF02_AG   Urban
  OAZ34_CIRCB_2017   29                      \-                          E138A                        \-                     G          Urban
  BJ11_CIRCB_2017    161                     \-                          Y188YH                                              CRF02_AG   Rural
  TJ30_CIRCB_2017    71                      \-                          E138A                                               CRF02_AG   Rural

Discussion {#sec017}
==========

With the increase risk of emerging drug resistance viruses in developing countries, HIV drug resistance (HIVDR) monitoring is therefore a capital component to support the adherence of patients and consequently pragmatic interventions with respect to the first-line ARV regimens. In this study, the Pre-treatment (PDR) prevalence rate was found to be 9.8%. Keeping in mind that the new surveillance method revised in 2014 by the WHO to monitor PDR in populations initiating ART involves generating a national representative prevalence estimate among this population \[[@pone.0235958.ref029]\], our findings suggest that PDR is at a moderate level at these settings, in accordance with previously described PDR WHO survey method of populations within a specified geographic area \[[@pone.0235958.ref029]\]. Our results are in accordance with previous studies carried out in the centre region Yaounde-Cameroon reporting drug-resistance mutation in population initiating ARV ranging from 4.9% to 24% \[[@pone.0235958.ref021],[@pone.0235958.ref023]--[@pone.0235958.ref026]\]. A recent study characterising a national representation of PDR in Cameroon following recent guidelines by WHO showed PDR resistance in Cameroon to be 10.4% \[[@pone.0235958.ref031]\]. This would suggest that though standard first-line treatment may remain effective, their efficacy is been affected as rate of PDR is on the rise. Studies conducted in other African countries show drug resistance mutation in populations initiating ARV to be; 11.5% (Mali), 9.2% (South Africa), 9.2% (Kenya), 4.2% (Morocco) \[[@pone.0235958.ref032]--[@pone.0235958.ref035]\]. In Europe precisely in the UK PDR has been found to reach right up to 14% \[[@pone.0235958.ref036]\]. Rates as high as 25% of PDR has been reported in the USA \[[@pone.0235958.ref037]\]. Of note most of these studies accessed transmitted drug resistance in naïve patients as distinguished now from pre-treatment drug resistance as per WHO revision in 2014 \[[@pone.0235958.ref029]\]. The differences in prevalence of PDR can be due to several factors; among which we could have the nature of the study (cross-sectional versus longitudinal), as longitudinal studies has been shown to have a lower level of drug resistance in naïve population compared to cross-sectional \[[@pone.0235958.ref008]\]. Secondly, differences in data among countries may also have resulted from specific biological and cultural characteristics as they relate to national epidemics, such as transmission routes, the proportion of non-B viruses and prescription guidelines \[[@pone.0235958.ref008]\]. Finally discrepancies can be further explained by the fact that, there are different algorithms available to the public domain which are routinely used for drug resistance interpretation and can therefore give results which are more or less similar, depending on the capacity of these tools to detect mutations \[[@pone.0235958.ref005]\]. However, the Stanford HIVdb algorithm version 8.5 known for its high sensitivity in the HIVDR detection was used in our study.

Our study showed a majority of mutations to NNRTIs (about two times higher than resistance mutations to NRTIs). There were no mutations to PIs detected in our study. This can be explained by the fact that majority of the population under HAART are not exposed to protease inhibitors which are generally reserved for second line treatment in our setting. Therefore the rate of drug resistance mutations conferring resistance to PI among populations initiating ARV is minimal. This is in accordance with a previous study which showed that only secondary mutations associated with PIs were detected in drug naïve patients in Cameroon during 2000 to 2002 \[[@pone.0235958.ref038]\]. However, another study in 2006 detected primary resistance to PI among naïve patients in Cameroon, revealing a rate as high as 7.4% \[[@pone.0235958.ref039]\]. This could be explained by the fact that the study had a larger sample size and the utilisation of deep sequencing method was employed which could detect minor mutations conferring resistance to PIs. Of note patients in the rural setting presented with resistance only to the NNRTIs in our study. This is in conformity of a recent study in Cameroon that showed presence of mutation to NNRTIs among naïve patients in rural areas only, with prevalence of PDR to NNRTI being 4.3% \[[@pone.0235958.ref031]\]. Another study in rural Cameroon showed PDR among population initiating ARV to be 4.8% \[[@pone.0235958.ref040]\]. The low prevalence experienced in rural areas could be explained by the fact that these areas have not been exposed to ARV for a very long period as compared to urban areas where ARV have been the main stay. The low genetic variability of these drugs can also influence their apparition. However there have been an increase in trend of PDR amongst populations initiating ARV in Cameroon from 0% in 1996--99 to 12.3% in 2007 \[[@pone.0235958.ref040]\] with this increase experienced more in NNRTIs. A recent retrospective study by Hassan et al in Kenya \[[@pone.0235958.ref041]\] using next generation sequencing (NGS) showed 24% of participants had at least one PDR variant with 8% to NRTIs, 6% to NNRTIs and 12% to PIs. The higher PDR found in their study when compared to ours is explained by the fact they used a more sensitive sequencing technique which detects mutation variants which cannot be detected using the standard sanger sequencing method. However the prevalence of NRTIs and NNRTIs is similar to that of our study. Similarly, a study conducted by Mbunkah *et al* in Cameroon \[[@pone.0235958.ref042]\] using NGS on dried blood spots found a low prevalence of transmitted drug resistance most especially in PIs, as fewer patients (\<5%) are exposed to these regimens in the country \[[@pone.0235958.ref005],[@pone.0235958.ref042]\]. Therefore, efforts for continuous surveillance monitoring for PDR should be intensified with NGS emphasis laid on rural areas that would be much more exposed to HIV drug-resistance as ART scale-up increases.

The mutation E138A found both in rural and urban setting confers low-level resistance to second generation NNRTIs and their presence alone or in conjunction with the mutation M138I causes decreased susceptibility of the virus to ETV and RPV \[[@pone.0235958.ref043]\]. This mutation has been found to occur between 0.5 to 5% among naïve patients \[[@pone.0235958.ref044]\]. The mutation Y188YH (quasi-specie) found only in the rural setting renders an intermediate level of resistance to the first-line NNRTIs \[[@pone.0235958.ref045]\].

In the urban setting, mutations conferring resistance to both NRTIs and NNRTIs but not PIs were found. The most common mutation to NRTIs found in our study was M41L (13.33%, 2/15). The mutation M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to Zidovudine (AZT) and Stavudine (d4T) and contribute to reduced Didanosine (ddI), Abacavir (ABC) and Tenofovir (TDF) susceptibility \[[@pone.0235958.ref046]\]. Of note the mutation K65R was found in one naïve patient. This mutation has mostly been described in patients under HAART but has hardly been found in patients' naïve to ARV therapy \[[@pone.0235958.ref047]\]. K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to Lamivudine (3TC) and Emtricitabine (FTC) but has also been found to increase susceptibility to AZT \[[@pone.0235958.ref048]\]. The emergence of K65R in naïve patients in our study strongly suggest reduced efficacy of first line regimens, hence the need for proper surveillance of this mutation among this population. The mutation M184V which on its own confers high level resistance to 3TC and FTC (about 100-fold increase) \[[@pone.0235958.ref049]\] was detected amongst these patients. The presence of this mutation could be explained by the fact 3TC is one of the principal drugs used in first-line therapy in Cameroon and equally constitute the backbone in the PMTCT of HIV. However, TDF in the presence of 3TC has been shown to induce M184V mutation which enhances the efficacy of 3TC-TDF combination \[[@pone.0235958.ref048]\]. The mutations k103N, E138G, P225H. K238T, V179E, M230L and E138A found in the participants in the urban setting conferred resistance to NNRTIs. K103N and M230L conferred high level resistance to the first-line NNRTIs. These findings are similar to that reported in a similar study in an urban setting in Cameroon \[[@pone.0235958.ref050]\]. The presence of these mutation is understood because Efavirenz EFV and Nevirapine (NVP) are molecules widely used in the first-line regimen and in addition nevirapine is the key antiretroviral for the PMTCT in Cameroon.

As pertaining to HIV-1 genetic variability, the phylogenetic analysis of the protease-reverse transcriptase *pol* region of the sequences in both settings revealed a marked genetic diversity most predominantly in the rural setting than urban. The CRF02_AG was the most represented strain in this region, in accordance with studies in other regions of Cameroon showing the prevalence of this strain \[[@pone.0235958.ref019],[@pone.0235958.ref050]\]. It has been shown that the CRF02_AG strain have a biologic advantage over parental strains, including a possibly higher replicative fitness and/or transmission capacity \[[@pone.0235958.ref051]\]. In addition the founder effect has also been argued for the predominance of CRF02_AG in West Central Africa which stipulates that the recombinant strain first introduced in a particular area, consequently get established in a population before other subtypes enter into the scene \[[@pone.0235958.ref051]\]. These could explain the predominance of the CRF02_AG strain in our study.

Finally, in both settings we found no association between CD4 staging (immune status), subtype distribution and the occurrence of drug resistance mutation. Our results are in accordance with a similar study done in the Centre region (Yaounde) Cameroon in 2014 \[[@pone.0235958.ref005]\]. However further studies with larger sample size are recommended to better affirm our findings.

Study limitations {#sec018}
=================

This study had some limitations which include, the fact that we used conventional Sanger sequencing which does not detect minor virus populations if frequencies are less than 20--25% of the entire viral population found within an infected individual. Therefore, minor mutations that have been shown to affect ARV drug susceptibility could not have been detected following our method. Furthermore, the use of deep sequencing for full length would have help in delineating potential new viral strain herein reported as unclassified. Also, the small sample size in our study could have an effect on the overall estimates of PDR; another limitation is our criteria for classifying drug naïve individual based solely on the testimonies of our patients, as some could have information bias about their status, thus supporting the measurement of drug concentration in future studies. The lack of viral load testing also limited the ability in assessing the effect of plasma viral load on PDR. This concept could now be easily addressed as viral load as become free of charge in the Cameroon ART program since January 2020.

Conclusion {#sec019}
==========

PDR was at a moderate rate in the two settings and higher within the urban populations. Though CRF02_AG is predominant in both urban and rural setting, viral diversity was found to be higher within the rural population. We found no association between HIV subtypes, CD4 staging and the occurrence of PDR mutation amongst these patients. Our findings suggest that there is need for close virological monitoring, use of NNRTI-sparing regimens, or HIV-1 genotyping for patients initiating ART in urban settings, especially with the presence of K65R mutation that jeopardizes the effectiveness of the current preferred first line ART.

We are thankful to patients who provided their consent for enrolment, and to administrative, clinical and technical staffs of the study sites for facilitating study implementation. The present study was conducted within the frame of research theses of Dr Shu Emile Nforbih and Dr Odine Padimel Kome at the Faculty of Medicine and Biomedical Sciences of the University of Yaounde I.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript provides information about the prevalence of HIV drug resistance in a small population of Cameroonian drug-naïve patients enrolled just in 4 months. In addition, the authors tried to find potential correlations between drug resistance and viral load or CD4 cell count, but due to the low number of enrolled individuals, no evidence for that was found. Thus, valuating the clinical impact of drug resistance in this kind of population remains challenging. In order to have a real overview of drug resistance in urban and rural area, and to really evaluate its clinical implication, more patients should be tested in a longer time period. This is the most important limitation for this study, that should be accurately stressed along all the manuscript.

Below are major comments:

1\) The authors asserted to have considered for their study pre-treatment HIV drug resistance (PDR) mutations, defined like transmitted or acquired drug resistance. According to what the authors wrote, these mutations may have been transmitted at the time of infection (TDR), or it may be acquired by prior ARV drug exposure. However, which mutations the authors used for their analysis remain unclear. A list with all the NRTI, NNRTI, and PI resistance mutations used for this study should be added in the supplementary material. For example, were the revertant mutations at RT position 215 considered in this list? If not, these mutations should be added for their role in drug resistance. These revertants might easily develop in T215Y/F and their presence by standard sequencing may indicate the presence of T215Y/F as a minority variant.

2\) Results, "Prevalence of HIV-1 Drug Resistance" paragraph. The authors stated that the PDR prevalence in rural and urban setting is 12.9% and 6.7%, respectively. It is not clear if this prevalence reflects the number of patients carrying at least one drug resistance. Please, clarify. The authors should also define clearly the number of patients carrying at least one NRTI and NNRTI mutation.

3\) In order to better evaluate drug resistance mutation patterns, the authors should add a table that summarizes for each one of the 6 patients carrying drug resistance, viral load, CD4, drug resistance mutations, subtype, and location of ART facility where the diagnosis was done (urban or rural).

4\) Discussion section. The authors stated that their study "showed a majority of mutations to NNRTIs (52.94%) than NRTIs (47.06%)". The prevalence of NRTI and NNRTI resistance should be reported on the overall population, and not, as done, on the 6 patients infected by drug resistant virus.

5\) Discussion section. The authors should compare their results with the most recent literature published on this field in Africa. In a recent paper based on NGS, Hassan et al defined the prevalence of drug resistance mutations in HIV-1 infected drug naïve patients from rural area of Kenya (Hassan et al., PloS One 2019). The authors reported a 24.0% of participants with at least one drug resistance, 12% against PI, 8.0% against NRTI and 6% against NNRTI. Despite the use of NGS, the prevalence of NRTI and NNRTI resistance in this paper is quite similar to those reported by Fokam et al. Differently, the prevalence of PI resistance that is zero in Fokam et al. is similar to that reported by another Cameroonian paper using NGS technology (Koizumi, JAC 2006).

Minor revision:

1\) Abstract and Results: Please, report drug resistance mutation without quasispecies (i.e. no M41ML but M41L).

2\) Results, Subtypes of HIV-1 Protease-Reverse Transcriptase sequences paragraph. Instead of A1/F2 subtype, define the exact recombinant form of this sequence.

3\) Results, Subtypes of HIV-1 Protease-Reverse Transcriptase sequences paragraph. Please, revise the sentence "the rural setting showed more two more genetic variant \[8 subtypes; A1 (3), G (1), F2 (1), CRF02_AG (21), CRF06_cpx (1), CRF11_cpx (1), CRF18_cpx (1) and A1/F2 (1)\], compared to the Urban setting \[5 subtypes A1 (3), G (3), F2 (1), CRF02_AG (23) and CRF18_cpx (1)\]." What does "more two more genetic variant" mean? Add the prevalence of subtypes in rural and urban settings, and p-value.

4\) Figure 1, resolution should be improved

5\) Please, revise reference 10. The HIV drug resistance report 2017 is available at the following link: <https://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/>

6\) Authors used PDR or DRM interchangeably. Please, use an uniform terminology along all the manuscript.

Reviewer \#2: This work quantifies the prevalence of pre-treatment drug resistance (PDR) in both rural and urban settings in Cameroon. A total of 61 sequences from 61 patients were analysed for NNRTIs and NRTIs resistance mutations. Fifteen resistance mutations were found in 4 patients from the urban setting compared with only two mutations (NNRTIs only) in two patients from the rural setting. Comparison between rural versus urban setting or level of CD4 are limited by the small sample size. The manuscript needs careful reading to correct few typos or English wording. I have only few minor comments

1\. There are only few mutations observed in few patients so the complete list of mutations for the four patients from the urban setting should be given.

2\. It is somewhat over-interpreted to consider that the difference in CD4 between urban and rural of 184 vs. 161 indicate a delay in diagnosis. Both IQR are very large likely as the range.

3\. Comparing the level of CD4 and the prevalence of mutations shows no statistical difference likely due to the small sample size. I'm surprised that the level of HIV-1 RNA was not available in the study to compare the presence of mutations according to the level of viral load at genotyping time. I guess that the CD4 count is a proxy of the level of viral load based on the correlation between HIV-1 RNA and CD4 cell count. This point should be discussed.

4\. In the discussion Section, I'm not convinced that discrepencies between studies can be explained by the different algorithms used. I understood that the percent gives for the studies are % of resistance mutations not resistance to drugs. The difference in the list of mutations used in the different algorithms is marginal.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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RESPONSE TO COMMENTS

Journal Requirements

Comment \#1: Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming.

Authors: We thank the academic editor for this comment. We have corrected the whole document to ensure the manuscript follows the PLOS ONE style template found on the shared link.

Comment \#2: Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed) - \"written/verbal\" is not sufficient.

Authors: We thank the academic editor for this pertinent remark. The statement has been revised as follows (see page 8, lines 280-293):

"Administrative approval for the study was issued by the Regional Delegation of Public Health of the Northwest region and from the Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (Ref. N° 2112/016L/CIRCB/DIR/CL); ethical approval for the research was obtained from the Cameroon National Ethics Committee for Research on Human Health (Ref. N° 2017/03/893/L/CNERSH/SP), and the Institutional Review Board (IRB) of Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I (Ref. N° 211/UYI/FMSB/VDRC/CSD). Following study information to each respondent, a written informed consent was obtained after having been clearly intimated with the objectives, methodology, advantages and potential risks involved in the study. Participation was voluntary throughout the study and any participant was free to decline participating in the study at any time without any prejudice. Participants were treated equally irrespective of their social status and other related status. Confidentiality and privacy were ensured by using no identification information. Genotypic results were freely returned to participants for possible clinical benefits in their therapeutic management."

Comment \#3: You state "sample size of 61 participants was calculated\" with no description of any sample size calculation/the associated parameters.

Authors: We thank the academic editor for this remark. The detailed description of the sample size calculation has been provided in page 5, lines 135-143. The formula used is as follows:

N =( Z\^2 x (p)(1-p) )/(d² )

N - the minimum sample size

Z - 1.96 for a 95 % Confidence interval

Where: p -- prevalence of patients presenting with resistant strain; p=7.55% \[ref 5\]

d -- error margin set at 6%

The authors considered a 94% CI with an error margin set at 6%. Prevalence of 0.75 from previous studies by Fokam et al in same country was used for the sample size calculation. A sample size of 68 participants was obtained. Seventy treatment naïve patients were recruited, of these 63 samples amplified after RT-PCR and 61 sequences were retained for analysis after sequencing reaction. Analysis was done based on the 61 samples retained.

Comment \#4: Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses.

Authors: we thank the Academic editor for this remark, more clarifications have been made in the manuscript under methodology (sample collection), at page 6, lines 218-223.

Comment \#5: We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed

Authors: We thank the academic editor for this very pertinent remark. We acknowledge some minor overlapping which has been rephrased.

Comment \#6: Thank you for stating the following financial disclosure: \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript\" Please address the following queries: Please clarify the sources of funding

Authors: We thank the Academic editor for this pertinent comment and remark. We acknowledge this mistake on our part. The source of funding has been included on the section titled 'Funding" in the manuscript and corresponding disclosure statement stated.

Comment \#7: Thank you for stating the following in your Competing Interests section: \"None\"

Authors: We thank the academic editor for this pertinent remark. These remarks have been taken into account accordingly in the section labeled "Competing interest" in the manuscript. These have equally been addressed on the online completion form.

 

REVIEWER'S COMMENTS TO AUTHOR

Reviewer \#1

Major comments:

Comment \#1: The authors asserted to have considered for their study pre-treatment HIV drug resistance (PDR) mutations, defined like transmitted or acquired drug resistance. According to what the authors wrote, these mutations may have been transmitted at the time of infection (TDR), or it may be acquired by prior ARV drug exposure. However, which mutations the authors used for their analysis remain unclear. A list with all the NRTI, NNRTI, and PI resistance mutations used for this study should be added in the supplementary material. For example, were the revertant mutations at RT position 215 considered in this list? If not, these mutations should be added for their role in drug resistance. These revertants might easily develop in T215Y/F and their presence by standard sequencing may indicate the presence of T215Y/F as a minority variant.

Authors: We thank the reviewer \#1 for this very pertinent comment. As stated in the methodology section; paragraph 5 of analysis, analysis for drug resistance mutations was done using the HIVdb algorithm (<http://hivdb.standford.edu/>) version 8.5. Following the high precision remark on the revertant mutations at RT position 215, indeed it was considered in the list of mutations from Stanford HIVdb used for analysis. None of the patients had these mutations. A list with all the NRTI, NNRTI and PI resistance mutations has been added in the supplementary material as stated by the reviewer \#1. See page 7, lines 266-270.

Comment \#2: Results, "Prevalence of HIV-1 Drug Resistance" paragraph. The authors stated that the PDR prevalence in rural and urban setting is 12.9% and 6.7%, respectively. It is not clear if this prevalence reflects the number of patients carrying at least one drug resistance. Please, clarify. The authors should also define clearly the number of patients carrying at least one NRTI and NNRTI mutation.

Authors: we thank the reviewer \#1 for this remark, the comment is very pertinent. Of the 6 patients who had drug resistances in both settings, 4 patients in the urban setting had at least one drug resistance (12.9%) while 2 patients (6.7%) had at least one drug resistance in the rural setting. The statement has been rephrased for better clarification on the identified section on the manuscripts. See details in pages 9-10, lines 335-339.

Comment \#3: In order to better evaluate drug resistance mutation patterns, the authors should add a table that summarizes for each one of the 6 patients carrying drug resistance, viral load, CD4, drug resistance mutations, subtype, and location of ART facility where the diagnosis was done (urban or rural).

Authors: we thank the reviewer \#1 for this remark, the comment is very pertinent. The summarized table 3 has been added accordingly. See pages 11-12, lines 389-393.

Comment \#4: Discussion section. The authors stated that their study "showed a majority of mutations to NNRTIs (52.94%) than NRTIs (47.06%)". The prevalence of NRTI and NNRTI resistance should be reported on the overall population, and not, as done, on the 6 patients infected by drug resistant virus.

Authors: we thank the reviewer \#1 for this pertinent remark showing the detailed reading of the submission package. Appropriate corrections has been made accordingly on paragraph 2, discussion section. See page 13, lines 425-426.

Comment \#5: Discussion section. The authors should compare their results with the most recent literature published on this field in Africa. In a recent paper based on NGS, Hassan et al defined the prevalence of drug resistance mutations in HIV-1 infected drug naïve patients from rural area of Kenya (Hassan et al., PloS One 2019). The authors reported a 24.0% of participants with at least one drug resistance, 12% against PI, 8.0% against NRTI and 6% against NNRTI. Despite the use of NGS, the prevalence of NRTI and NNRTI resistance in this paper is quite similar to those reported by Fokam et al. Differently, the prevalence of PI resistance that is zero in Fokam et al. is similar to that reported by another Cameroonian paper using NGS technology (Koizumi, JAC 2006).

Authors: we thank the reviewer \#1 for this pertinent update. The respective manuscripts have been read and used in our discussion section. See page 13, lines 444-452.

Minor comments:

Minor comment \#1: Abstract and Results: Please, report drug resistance mutation without quasi species (i.e. no M41ML but M41L).

Authors: we thank the reviewer \#1 for this remark. The corrections have been taken into account in the manuscript as recommended.

Minor comment \#2: Results, Subtypes of HIV-1 Protease-Reverse Transcriptase sequences paragraph. Instead of A1/F2 subtype, define the exact recombinant form of this sequence.

Authors: we thank the reviewer \#1 for this comment. On the list of circulating recombinant form (CRF), we did not find any classified CRF with these two distinct subtypes.

Minor comment \#3: Results, Subtypes of HIV-1 Protease-Reverse Transcriptase sequences paragraph. Please, revise the sentence "the rural setting showed more two more genetic variant \[8 subtypes; A1 (3), G (1), F2 (1), CRF02_AG (21), CRF06_cpx (1), CRF11_cpx (1), CRF18_cpx (1) and A1/F2 (1)\], compared to the Urban setting \[5 subtypes A1 (3), G (3), F2 (1), CRF02_AG (23) and CRF18_cpx (1)\]." What does "more two more genetic variant" mean? Add the prevalence of subtypes in rural and urban settings, and p-value.

Authors: we thank the reviewer \#1 for this comment. The word "more two more genetic variant' is a duplication which has been corrected. Actually, the statement was aimed at informing the rural setting had two genetic variants which the urban setting didn't. These variants were CRF06_cpx and CRF11_cpx. The prevalence of subtypes was evaluated based on the clade. Participants were classified as either having CRF02_AG or non CRF02_AG and based on the setting a non-significant p-value of 0.715 was obtained. This is explained in paragraph 1 of "Results, Subtypes of HIV-1 Protease-Reverse Transcriptase sequences paragraph." See page 10, lines 356-366.

Minor comment \#4: Figure 1, resolution should be improved

Authors: we thank the reviewer \#1 for this remark. The resolution has been improved upon as can be seen on the attached file.

Minor comment \#5: Please, revise reference 10. The HIV drug resistance report 2017 is available at the following link: <https://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/>

Authors: we thank the reviewer \#1 for this remark showing the detailed reading of the submission package. The reference has been corrected on the manuscript.

Minor comment \#6: Authors used PDR or DRM interchangeably. Please, use an uniform terminology along all the manuscript.

Authors: we thank the reviewer \#1 for this remark. The whole document has been reviewed and corrections made accordingly, to read only PDR.

 

Reviewer \# 2

Minor comments

Minor comment \#1: There are only few mutations observed in few patients so the complete list of mutations for the four patients from the urban setting should be given.

Authors: we thank the reviewer \#2 for this suggestion. The suggestion goes in line with a comment raised by reviewer \#1. The lists of mutations and related data have been represented on table 3.

Minor comment \#2: It is somewhat over-interpreted to consider that the difference in CD4 between urban and rural of 184 vs. 161 indicate a delay in diagnosis. Both IQR are very large likely as the range.

Authors: we thank the reviewer \#2 for this pertinent comment. This statement has been removed from the text.

Minor comment \#3: Comparing the level of CD4 and the prevalence of mutations shows no statistical difference likely due to the small sample size. I'm surprised that the level of HIV-1 RNA was not available in the study to compare the presence of mutations according to the level of viral load at genotyping time. I guess that the CD4 count is a proxy of the level of viral load based on the correlation between HIV-1 RNA and CD4 cell count. This point should be discussed.

Authors: we thank the reviewer \#2 for this very pertinent remark. Indeed, we also had the same need in viral load testing throughout for the study. However, this could not be realized because viral load testing was not recommended at ART initiation and the cost of viral load testing was not available. Of note, at the time of the study, viral loads were still payable in Cameroon, and the Cameroon government has only recently adopted free viral loads since January 2020. This has been highlighted in the discussion section, under study limitation.

Minor comment \#4: In the discussion Section, I'm not convinced that discrepancies between studies can be explained by the different algorithms used. I understood that the percent gives for the studies are % of resistance mutations not resistance to drugs. The difference in the list of mutations used in the different algorithms is marginal.

Authors: we thank the reviewer \#2 for this remark. Indeed, resistance mutations are expressed in percentages. Moreover, the sequencing method has a very important role in the detection of the resistance mutations. For example, the sanger sequencing technic used in our study does not detect viruses with major mutations like M46I unlike other WHO major mutations like K103N that can be easily detected because of its high replicative fitness. The sequencing method used can therefore be improved for better identification of mutations if further deep sequencing is performed, which can henceforth explain the difference in the detected mutations.

In a nutshell, we are very appreciative for your informed review and we hope our revised version would meet your approval of the revised manuscript.

Sincerely,

Dr. Joseph Fokam

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Reviewers\' comments:

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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